Summer 2026, Fall 2026
International Recruitment and Development Program Intern
Updated on 7/21/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Neukirchen-Vluyn, Germany
Hybrid
Hybrid role in Neuss, Germany; some on-site days required.
 People & HR (1) |
|---|
Get referred to Johnson & Johnson
Find people who can refer or advise you
- First year of either a full-time MBA or master’s degree program and will be graduating after September 2026
- Available full-time for a period of at least 8-12 weeks between June and September 2026
- Fluent in English and the language of the country where the internship assignment is located
- Legally authorized to work permanently (i.e., without time limitations, without restrictions, or without need for work sponsorship) in the country where the internship assignment is located
- Have three years or more of relevant professional experience prior to enrolling in a full-time master’s level degree program
- Proven leadership capabilities
- Ability to develop solutions using data-driven insights
- Lead significant business projects with real-life implications and present your analysis and results to senior leaders
- Make a significant impact on the business from your first day
- Be an integral member of a cross-functional team
- Participate in activities designed to encourage community amongst interns and from structured development goals to help you drive success
- Passion for healthcare
- Strategic mindset
- Exceptional leadership, communication, and interpersonal skills
- Thrive in a highly complex, global work environment
- Take initiative to set priorities and exceed goals
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
Find people who can refer or advise you
Simplify's Take
What believers are saying
- J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
- FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
- J&J's 2026 revenue will exceed $100 billion for the first time in history.
What critics are saying
- 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
- Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
- Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.
What makes Johnson & Johnson unique
- J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
- Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
- J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
- J&J's oncology portfolio gained multiple FDA approvals in early 2026.
- MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -1%• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation
Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.
Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.
Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.
Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.